Status:

TERMINATED

Pain, Opioids and Pro-Inflammatory Immune Responses

Lead Sponsor:

University of California, Los Angeles

Conditions:

Pro-inflammatory Activity

Immunologic Activity Alteration

Eligibility:

All Genders

21-40 years

Phase:

PHASE1

Brief Summary

Providing pain management to the patient who abuses prescription opioids presents a clinical challenge, not only due to concerns about "drug-seeking", but because they have increased sensitivity to pa...

Detailed Description

Both acute pain and opioid administration have been shown to induce a systemic pro-inflammatory response. However, the presence of these inflammatory responses is unknown in situations where a co-occu...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • male and non-pregnant female, non-smoking adults in good general health
  • between the ages of 21-40 years old
  • fluent in English with willingness to participate in the research study
  • Supplementary Inclusion Criteria: Prescription Opioid Abusers
  • DSM-IVR diagnosis of prescription opioid abuse or dependence disorder
  • compliance in treatment and on a stable dose of buprenorphine (6-24mg/day) x at least 10 days prior to screening
  • Participation in an ISAP treatment program or a qualified community-based opioid treatment program or private clinic for the entire duration of their study participation
  • Exclusion criteria:
  • regular use of any medication that influences immune status or immune system function
  • regular use of a medication that influences pain perception, including opioids (\* only for healthy subjects population\*)
  • Regular use of a medication that influences pain perception, except for buprenorphine (\*\* only for POA population\*\*)
  • known hypersensitivity to opioids or no previous opioid exposure (\*only healthy controls)
  • presence of acute or chronic pain syndrome
  • neuropsychiatric illness (i.e., peripheral neuropathy, schizophrenia) known to affect pain perception
  • presence of chronic immune compromise (hepatitis C, HIV) or acute infection within the last four weeks
  • current or past history of high blood pressure, heart disease, or stroke, or currently have a pacemaker.
  • current DSM-IV diagnosis
  • BMI less than 18.5 or greater than 29.9
  • History of sleep apnea

Exclusion

    Key Trial Info

    Start Date :

    July 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2012

    Estimated Enrollment :

    21 Patients enrolled

    Trial Details

    Trial ID

    NCT01210066

    Start Date

    July 1 2010

    End Date

    May 1 2012

    Last Update

    December 29 2016

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    UCLA School of Nursing

    Los Angeles, California, United States, 90095

    Pain, Opioids and Pro-Inflammatory Immune Responses | DecenTrialz